Literature DB >> 17888545

Is erythropoietin gene a modifier factor in amyotrophic lateral sclerosis?

Serena Ghezzi1, Roberto Del Bo, Marina Scarlato, Martina Nardini, Cecilia Carlesi, Alessandro Prelle, Stefania Corti, Michelangelo Mancuso, Chiara Briani, Gabriele Siciliano, Luigi Murri, Nereo Bresolin, Giacomo Pietro Comi.   

Abstract

To investigate the role of erythropoietin (EPO) as genetic determinant in the susceptibility to sporadic amyotrophic lateral sclerosis (SALS). We sequenced a 259-bp region spanning the 3'hypoxia-responsive element of the EPO gene in 222 Italian SALS patients and 204 healthy subjects, matched for age and ethnic origin. No potentially causative variation was detected in SALS subjects; in addition, two polymorphic variants (namely C3434T and G3544T) showed the same genotype and haplotype frequencies in patients and controls. Conversely, a weak but significant association between G3544T and age of disease onset was observed (p=0.04). Overall, our data argue against the hypothesis of EPO as a genetic risk factor for motor neuron dysfunction, at least in Italian population. However, further studies on larger cohort of patients are needed to confirm the evidence of EPO gene as modifier factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888545     DOI: 10.1016/j.neurobiolaging.2007.08.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  2 in total

1.  Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia.

Authors:  Anne Kästner; Sabrina Grube; Ahmed El-Kordi; Beata Stepniak; Heidi Friedrichs; Derya Sargin; Judith Schwitulla; Martin Begemann; Ina Giegling; Kamilla W Miskowiak; Swetlana Sperling; Kathrin Hannke; Anna Ramin; Ralf Heinrich; Olaf Gefeller; Klaus-Armin Nave; Dan Rujescu; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

2.  Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  P Janik; H Kwiecinski; B Sokolowska; I Niebroj-Dobosz
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.